Louisville, KY (November 1, 2012)

Neuronetrix yesterday presented preliminary clinical trial results for the COGNISION™ System, its proprietary device for the early diagnosis of Alzheimer’s disease and other neurological disorders. The results were presented by K.C. Fadem, Neuronetrix President, at CTAD 2012 (Clinical Trials on Alzheimer’s Disease) in Monte Carlo. CTAD was attended by some 600 leading Alzheimer’s researchers, clinicians, and industry representatives from around the world. The preliminary results, based upon 106 subjects (total target = 200), demonstrated that COGNISION™ could correctly discriminate mild Alzheimer’s sufferers from age-matched controls approximately 80% of the time.

The multi-center trial is being conducted at seven sites: UPenn, Duke, Univ. of Kentucky, Norton Neuroscience, Boston Center for Memory, The Memory Clinic in Bennington VT, and Premiere Research Institute in West Palm Beach FL.

“We are very encouraged by these preliminary results” said Mr. Fadem. “As the number of subjects in the trial continues to increase, it is likely that the ability of the COGNISION™ System to correctly classify subjects with early stage Alzheimer’s disease will improve even further. This also suggests a possible role for COGNISION™ in drug development, by providing a physiological cognitive biomarker to evaluate the pro-cognitive effects of novel therapies. Given the recent challenges in Alzheimer’s disease therapeutic trials, this could be especially important.”

The COGNISION™ System is a proprietary event-related potentials (ERP) device which can be used by academic and clinical researchers in investigations of many cognitive processes and neurological disorders. The COGNISION™ System includes a user-friendly device to record electroencephalographic (EEG) data and an online database to store subject information. The system combines many useful and unique features, which are detailed in the COGNISION™ Product Brochure. Upon approval by the FDA, COGNISION™ will be used by clinicians for the evaluation of Alzheimer’s disease and other cognitive disorders.